Aura Biosciences (NASDAQ:AURA) Reaches New 52-Week High – Here’s Why

Aura Biosciences, Inc. (NASDAQ:AURA)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $9.54 and last traded at $8.90, with a volume of 5880551 shares changing hands. The stock had previously closed at $8.35.

Key Headlines Impacting Aura Biosciences

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: Aura closed an underwritten public offering that raised roughly $299.4 million gross, providing capital to advance its lead candidate bel?sar (AU?011) and other programs — a near?term liquidity boost that reduces financing risk for upcoming clinical and registration activities. Article Link
• Positive Sentiment: The company appointed Natalie Holles as CEO and reported accelerated patient screening toward Phase 3 CoMpass enrollment completion — management and operational progress that investors typically view as supportive for execution and upcoming clinical catalysts. Article Link
• Neutral Sentiment: When priced, the offering included pre?funded warrants and a plan to repurchase up to ~6.9M shares from Matrix Capital at $5.64 per share — a technical maneuver that may modestly offset float increases but has mixed implications depending on future warrant exercises. Article Link
• Negative Sentiment: The offering added 46,099,650 shares (including full exercise of the underwriters’ option) plus pre?funded warrants, which materially dilutes existing shareholders and can pressure the stock until clinical milestones validate value per share. Article Link
• Negative Sentiment: An analyst note flagged weaker near?term earnings expectations for Aura, which may temper sentiment until the company demonstrates trial outcomes or revenue progress. Article Link

Analysts Set New Price Targets

Several brokerages have weighed in on AURA. HC Wainwright increased their target price on Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research report on Friday, March 27th. Finally, Wall Street Zen raised shares of Aura Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $21.50.

Aura Biosciences Stock Up 6.6%

The firm has a market capitalization of $571.38 million, a price-to-earnings ratio of -4.97 and a beta of 0.37. The company has a 50-day moving average price of $6.56 and a 200-day moving average price of $6.01.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Monday, March 30th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. As a group, analysts forecast that Aura Biosciences, Inc. will post -1.63 earnings per share for the current year.

Insider Activity at Aura Biosciences

In other news, SVP Amy Elazzouzi sold 8,549 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $43,257.94. Following the transaction, the senior vice president directly owned 75,532 shares of the company’s stock, valued at approximately $382,191.92. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Janet Jill Hopkins sold 20,401 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $103,229.06. Following the sale, the insider owned 232,284 shares in the company, valued at approximately $1,175,357.04. This represents a 8.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 116,305 shares of company stock valued at $611,230. 6.30% of the stock is owned by corporate insiders.

Institutional Trading of Aura Biosciences

Institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Aura Biosciences during the first quarter valued at approximately $137,000. Invesco Ltd. bought a new stake in Aura Biosciences during the second quarter worth approximately $76,000. Nantahala Capital Management LLC lifted its position in Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock worth $13,257,000 after purchasing an additional 850,000 shares during the period. Ameriprise Financial Inc. boosted its stake in Aura Biosciences by 31.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company’s stock valued at $529,000 after purchasing an additional 20,065 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in Aura Biosciences during the 2nd quarter valued at $102,000. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences is a clinical?stage biopharmaceutical company focused on the development of novel virus?like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non?ophthalmic settings, leveraging precision activation via near?infrared light to induce localized tumor cell apoptosis and stimulate anti?tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.